

7 References

Anarjan N, Jafarizadeh-Malmiri H, Nehdi IA, et al. Effects of homogenization process parameters on physicochemical properties of astaxanthin nanodispersions prepared using a solvent-diffusion technique. *International journal of nanomedicine*. 2015;10:1109.

Anton N, Saulnier P, Gaillard C, et al. Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules. *Langmuir*. 2009;25(19):11413-9.

Arpicco S, Battaglia L, Brusa P, et al. Recent studies on the delivery of hydrophilic drugs in nanoparticulate systems. *Journal of Drug Delivery Science and Technology*. 2016;32:298-312.

Ascierto PA and Marincola FM. Combination therapy: the next opportunity and challenge of medicine. *Journal of Translational Medicine*. 2011 07/21

Ashley JD, Quinlan CJ, Schroeder VA, et al. Dual Carfilzomib and Doxorubicin–Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma. *Molecular cancer therapeutics*. 2016;15(7):1452-9.

Bhalekar M, Upadhaya P and Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. *Applied Nanoscience*. 2017 February 01;7(1):47-57.

Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. *Advanced drug delivery reviews*. 2007;59(6):454-77.

Bougaret J, Leverd E, Bohn M-M, et al. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment. *Google Patents*; 2005.

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 2018;0(0):1-31.

Breitinger H-G. Drug synergy–mechanisms and methods of analysis. *Toxicity and Drug Testing*. 2012:143-66.

Cao X, Tai Y, Sun C, et al. Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique. *Journal of pharmaceutical and biomedical analysis*. 2005;39(1-2):39-45.

Cao X, Tai Y, Sun C, et al. Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique. *Journal of pharmaceutical and biomedical analysis*. 2005;39(1-2):39-45.

Carbone C, Musumeci T, Lauro M, et al. Eco-friendly aqueous core surface-modified nanocapsules. *Colloids and Surfaces B: Biointerfaces*. 2015;125:190-6.

Chatterjee A, Ronghe A, Padhye SB, et al. Antioxidant activities of novel resveratrol analogs in breast cancer. *Journal of biochemical and molecular toxicology*. 2018;32(1):e21925.

Chen S, Liang Q, Xie S, et al. Curcumin based combination therapy for anti-breast cancer: from in vitro drug screening to in vivo efficacy evaluation. *Frontiers of Chemical Science and Engineering*. 2016;10(3):383-8.

Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer research*. 2010;70(2):440-6.

Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacological reviews*. 2006;58(3):621-81.

Chowdhury N, Vhora I, Patel K, et al. Development of hot melt extruded solid dispersion of tamoxifen citrate and resveratrol for synergistic effects on breast Cancer cells. *AAPS PharmSciTech*. 2018;19(7):3287-97.

Cosco D, Paolino D, De Angelis F, et al. Aqueous-core PEG-coated PLA nanocapsules for an efficient entrapment of water soluble anticancer drugs and a smart therapeutic response. *European Journal of Pharmaceutics and Biopharmaceutics*. 2015;89:30-9.

Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. *Cancer*. 2018.

Daneshmand S, Golmohammadzadeh S, Jaafari MR, et al. Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization. *Journal of cellular biochemistry*. 2018;119(6):4251-64.

de la Lastra CA and Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Portland Press Limited; 2007.

Dos Santos PP, Paese K, Guterres SS, et al. Development of lycopene-loaded lipid-core nanocapsules: physicochemical characterization and stability study. *Journal of Nanoparticle Research*. 2015;17(2):107.

Drummond DC, Noble CO, Guo Z, et al. Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. *Journal of Pharmacology and Experimental Therapeutics*. 2009;328(1):321-30.

Ekambaram P and Sathali AAH. Formulation and evaluation of solid lipid nanoparticles of ramipril. *Journal of Young Pharmacists*. 2011;3(3):216-20.

Emanuela M, Giuseppe C, Sonia C, et al. Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead. *Bioorganic & medicinal chemistry letters*. 2018.

Fuchs AV and Thurecht KJ. Interfacial RAFT Miniemulsion Polymerization: Architectures from an Interface. *Macromolecular Chemistry and Physics*. 2015;216(12):1271-81.

Goa KL and Faulds D. Vinorelbine. *Drugs & aging*. 1994;5(3):200-34.

Greco F and Vicent MJ. Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. *Advanced drug delivery reviews*. 2009;61(13):1203-13.

Grobmyer SR, Iwakuma N, Sharma P, et al. *What is cancer nanotechnology?*: Springer; 2010.

Guideline IHT. ICH Q2B (May 1997). Validation of analytical procedures: methodology.

Guideline IHT. Stability testing of new drug substances and products. Q1A (R2), current step. 2003;4:1-24.

Gupta S, Kesarla R, Chotai N, et al. Systematic approach for the formulation and optimization of solid lipid nanoparticles of Efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. *BioMed research international*. 2017;2017.

Hajhashemi V, Ghafghazi T, Balali M, et al. Toxicological studies on an anticancer drug (HESA-A) with marine origin. *Medical Journal of Islamic Academy of Sciences*. 2001;14:145-9.

Health UDo, Services H, Food, et al. Guidance for industry nonclinical studies for the safety evaluation of pharmaceutical excipients. *Pharmacology/Toxicology* May. 2005.

Ivanov S, Zhuravsky S, Yukina G, et al. In vivo toxicity of intravenously administered silica and silicon nanoparticles. *Materials*. 2012;5(10):1873-89.

Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. *Drug discovery today*. 2006;11(17):812-8.

Jain A, Mishra SK, Vuddanda PR, et al. Targeting of diacerein loaded lipid nanoparticles to intra-articular cartilage using chondroitin sulfate as homing carrier for treatment of osteoarthritis in rats. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2014;10(5):e1031-e40.

Joshi SA, Chavhan SS and Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. *European Journal of Pharmaceutics and Biopharmaceutics*. 2010;76(2):189-99.

Kansal S, Tandon R, Verma PRP, et al. Development of doxorubicin loaded novel core shell structured nanocapsules for the intervention of visceral leishmaniasis. *Journal of microencapsulation*. 2013;30(5):441-50.

Kashif M, Andersson C, Hassan S, et al. In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index. *Scientific reports*. 2015;5.

Kothamasu P, Kanumur H, Ravur N, et al. Nanocapsules: the weapons for novel drug delivery systems. *Bioimpacts*. 2012;2(2):71-81.

Kou X, Kirberger M, Yang Y, et al. Natural products for cancer prevention associated with Nrf2–ARE pathway. *Food Science and Human Wellness*. 2013;2(1):22-8.

Koziara J, Oh J, Akers W, et al. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. *Pharmaceutical research*. 2005;22(11):1821-8.

Kreidieh FY, Moukadem HA and El Saghir NS. Overview, prevention and management of chemotherapy extravasation. *World journal of clinical oncology*. 2016;7(1):87.

Kulkarni SA and Feng S-S. Effects of Particle Size and Surface Modification on Cellular Uptake and Biodistribution of Polymeric Nanoparticles for Drug Delivery. *Pharmaceutical Research*. 2013 October 01;30(10):2512-22.

Kushwaha AK, Vuddanda PR, Karunanidhi P, et al. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. *BioMed research international*. 2013;2013.

Lambert G, Fattal E, Pinto-Alphandary H, et al. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. *Pharmaceutical research*. 2000;17(6):707-14.

Li Y, Zhao X, Zu Y, et al. A novel active targeting preparation, vinorelbine tartrate (VLBT) encapsulated by folate-conjugated bovine serum albumin (BSA) nanoparticles: Preparation, characterization and in vitro release study. *Materials*. 2012;5(11):2403-22.

Lu D, Chen E, Lu T, et al. Anticancer drug combinations, studies from different pathways. *Cell & Developmental Biology*. 2015a;4(5):166.

Malvia S, Bagadi SA, Dubey US, et al. Epidemiology of breast cancer in Indian women. *Asia-Pacific Journal of Clinical Oncology*. 2017;13(4):289-95.

Maurya L, Rajamanickam V, Narayan G, et al. Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): Formulation development, optimization and in vitro characterization. *Current drug delivery*. 2018.

Maurya L, Singh S, Vijayakumar M, et al. Lipid based aqueous core nanocapsules (ACNs) for encapsulating hydrophilic Vinorelbine bitartrate: Preparation, optimization, characterization and in vitro safety assessment for intravenous administration. *Current drug delivery*. 2018.

Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. *Molecular cancer therapeutics*. 2006;5(7):1854-63.

Mishra A, Vuddanda PR and Singh S. Intestinal lymphatic delivery of praziquantel by solid lipid nanoparticles: formulation design, in vitro and in vivo studies. *Journal of Nanotechnology*. 2014;2014.

Mishra B, Padaliya R and Patel RR. Exemestane encapsulated vitamin E-TPGS–polymeric nanoparticles: preparation, optimization, characterization, and in vitro cytotoxicity assessment. *Artificial cells, nanomedicine, and biotechnology*. 2017;45(3):522-34.

Monograph R. Resveratrol. Monograph. *Altern Med Rev*. 2010;15:152-8.

Montgomery DC. Design and analysis of experiments: John Wiley & Sons; 2017.

Mora-Huertas C, Fessi H and Elaissari A. Polymer-based nanocapsules for drug delivery. *International journal of pharmaceutics*. 2010;385(1):113-42.

National Center for Biotechnology Information. PubChem Compound Database; CID=445154 hpnngcaJ, 2019).

National Center for Biotechnology Information. PubChem Compound Database; CID=45055483 hpnngcaJ, 2019).

Ochiai N, Shimazaki C, Inaba T, et al. Effect of vinorelbine on the growth of human myeloma cell lines in vitro. *Leukemia research*. 2002;26(8):731-8.

Patel RR, Chaurasia S, Khan G, et al. Highly water-soluble mast cell stabiliser-encapsulated solid lipid nanoparticles with enhanced oral bioavailability. *Journal of microencapsulation*. 2016;33(3):209-20.

Patel RR, Kumar N, Khan G, et al. Investigation of Critical Variables of Core–Shell Polymer Lipid Hybrid Nanoparticles by Using Plackett-Burman Screening Design. *Advanced Science Letters*. 2014;20(5-6):923-32.

Pavillard V, Kherfella D, Richard S, et al. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. *British journal of cancer*. 2001;85(7):1077.

Purvin S, Vuddanda PR, Singh SK, et al. Pharmacokinetic and tissue distribution study of solid lipid nanoparticles of Zidovudine in rats. *Journal of Nanotechnology*. 2014;2014.

Saputra EC, Huang L, Chen Y, et al. Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer. *Cancer Research*. 2018.

Singh B, Vuddanda PR, Vijayakumar M, et al. Cefuroxime axetil loaded solid lipid nanoparticles for enhanced activity against *S. aureus* biofilm. *Colloids and Surfaces B: Biointerfaces*. 2014;121:92-8.

Singh RP, Sharma G, Sonali, et al. Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. *Colloids and Surfaces B: Biointerfaces*. 2016;141:429-42.

Singh S, Vijayakumar MR and Dewangan HK. Lipid Based Aqueous Core Nanocapsules (ACNs) for Encapsulating Hydrophilic Vinorelbine Bitartrate: Preparation, Optimization, Characterization and In vitro Safety Assessment for Intravenous Administration. *Current drug delivery*. 2018;15(9):1284-93.

Sinha D, Sarkar N, Biswas J, et al. Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. *Seminars in Cancer Biology*. 2016;40-41:209-32.

Smith RA and DeSantis CE. Breast cancer epidemiology. *Breast Imaging*. 2018.

Solanki AB, Parikh JR and Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design. *AAPS PharmSciTech*. 2007;8(4):43-9.

Srinivas NSK, Verma R, Kulyadi GP, et al. A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. *International journal of nanomedicine*. 2017;12:15.

Suh J, Kim D-H and Surh Y-J. Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk. *Archives of biochemistry and biophysics*. 2018;643:62-71.

Summerlin N, Soo E, Thakur S, et al. Resveratrol nanoformulations: challenges and opportunities. *International journal of pharmaceutics*. 2015;479(2):282-90.

Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. *Leukemia research*. 2009;33(1):129-39.

Thummar VR, Parasuraman S, Basu D, et al. Evaluation of in vivo antitumor activity of cleistanthin B in Swiss albino mice. *Journal of traditional and complementary medicine*. 2016;6(4):383-8.

Tolcher AW and Mayer LD. Improving combination cancer therapy: the CombiPlex® development platform. *Future Oncology*. 2018;14(13):1317-32. PubMed PMID: 29363994.

Udom D, Vigushin D, Linardou H, et al. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. *European Journal of Cancer*. 2000;36(2):177-82.

Van Heugen J, De Graeve J, Zorza G, et al. New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. *Journal of Chromatography A*. 2001;926(1):11-20.

van Meerloo J, Kaspers GJ and Cloos J. Cell sensitivity assays: the MTT assay. *Cancer cell culture*: Springer; 2011. p. 237-45.

Vardhan H, Mittal P, Adena SKR, et al. Long-circulating polyhydroxybutyrate-co-hydroxyvalerate nanoparticles for tumor targeted docetaxel delivery: Formulation, optimization and in vitro characterization. *European Journal of Pharmaceutical Sciences*. 2017;99:85-94.

Vassilomanolakis M, Koumakis G, Barbounis V, et al. Prevention of vinorelbine phlebitis with cimetidine. *Supportive care in cancer*. 2001;9(2):108-11.

Vijayakumar MR, Kosuru R, Singh SK, et al. Resveratrol loaded PLGA: d- α -tocopheryl polyethylene glycol 1000 succinate blend nanoparticles for brain cancer therapy. *RSC Advances*. 2016;6(78):74254-68.

Vijayakumar MR, Kosuru R, Singh SK, et al. Resveratrol loaded PLGA: d- α -tocopheryl polyethylene glycol 1000 succinate blend nanoparticles for brain cancer therapy. *RSC Advances*. 2016a;6(78):74254-68.

Vijayakumar MR, Kosuru R, Vuddanda PR, et al. Trans resveratrol loaded DSPE PEG 2000 coated liposomes: An evidence for prolonged systemic circulation and passive brain targeting. *Journal of Drug Delivery Science and Technology*. 2016b;33:125-35.

Vijayakumar MR, Kumari L, Patel KK, et al. Intravenous administration of trans-resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. *RSC Advances*. 2016b;6(55):50336-48.

Vijayakumar MR, Kumari L, Patel KK, et al. Intravenous administration of trans-resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. *RSC Advances*. 2016;6(55):50336-48.

Vijayakumar MR, Vajanthri KY, Balavigneswaran CK, et al. Pharmacokinetics, biodistribution, in vitro cytotoxicity and biocompatibility of Vitamin E TPGS coated trans resveratrol liposomes. *Colloids and Surfaces B: Biointerfaces*. 2016d;145:479-91.

Vrignaud S, Anton N, Passirani C, et al. Aqueous core nanocapsules: a new solution for encapsulating doxorubicin hydrochloride. *Drug development and industrial pharmacy*. 2013;39(11):1706-11.

Vuddanda PR, Mishra A, Singh SK, et al. Development of polymeric nanoparticles with highly entrapped herbal hydrophilic drug using nanoprecipitation technique: an approach of quality by design. *Pharmaceutical development and technology*. 2015;20(5):579-87.

Vuddanda PR, Rajamanickam VM, Yaspal M, et al. Investigations on Agglomeration and Haemocompatibility of Vitamin E TPGS Surface Modified Berberine Chloride Nanoparticles. *BioMed Research International*. 2014 08/04

Wan F, You J, Sun Y, et al. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. *International journal of pharmaceutics*. 2008;359(1):104-10.

Wang F, Dai W, Wang Y, et al. The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. *PloS one*. 2014;9(5):e97414.

Wang Y, Zheng Y, Zhang L, et al. Stability of nanosuspensions in drug delivery. *Journal of Controlled Release*. 2013 2013/12/28/;172(3):1126-41.

Webb MS, Johnstone S, Morris TJ, et al. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. *European journal of pharmaceutics and biopharmaceutics*. 2007;65(3):289-99.

Wong HL, Bendayan R, Rauth AM, et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. *Advanced drug delivery reviews*. 2007;59(6):491-504.

Yamada T, Egashira N, Imuta M, et al. Role of oxidative stress in vinorelbine-induced vascular endothelial cell injury. *Free Radical Biology and Medicine*. 2010;48(1):120-7.

Yin H, Liao L and Fang J. Enhanced permeability and retention (EPR) effect based tumor targeting: the concept, application and prospect. *JSM Clin Oncol Res*. 2014;2(1):1010.

Yoh K, Niho S, Goto K, et al. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. *Lung Cancer*. 2007;55(3):337-41.

You J, Wan F, de Cui F, et al. Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. *International journal of pharmaceutics*. 2007;343(1):270-6.

Yuanyai C and Nembhard HB. Chapter 8 - Design of Experiments: A Key to Innovation in Nanotechnology. *Emerging Nanotechnologies for Manufacturing*. Boston: William Andrew Publishing; 2010. p. 207-34.

Zacharchuk CM. Antineoplastic combinations containing HKI-272 and vinorelbine. *Google Patents*; 2018.

Zhang HY, Tang X, Li HY, et al. A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics. *International journal of pharmaceutics*. 2008;348(1):70-9.

Zhang J, Tong N, Chen Y, et al. Resveratrol protects against vinorelbine-induced vascular endothelial cell injury. *Toxicology mechanisms and methods*. 2013;23(9):665-71.

Zhang JA and Ahmad I. Vinorelbine compositions and methods of use. *Google Patents*; 2004.

zur Mühlen A, Schwarz C and Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism. *European Journal of Pharmaceutics and Biopharmaceutics*. 1998 1998/03/01;45(2):149-55.